What Is Sermorelin? Uses, Risks, and FDA Status
What Is Sermorelin?
Sermorelin is a synthetic peptide consisting of the first 29 amino acids of growth hormone-releasing hormone (GHRH). It was originally FDA-approved in 1997 under the brand name Geref for diagnosing and treating growth hormone deficiency in children. Although the branded product was discontinued in 2008 for commercial reasons, sermorelin has remained available through compounding pharmacies and is one of the most established peptides in anti-aging and hormone optimization medicine.
How Does Sermorelin Work?
Sermorelin works by binding to GHRH receptors in the anterior pituitary gland, stimulating the natural production and release of growth hormone. Unlike exogenous growth hormone (which bypasses the pituitary entirely), sermorelin preserves the body's natural feedback mechanisms. The pituitary still regulates how much GH is released, which reduces the risk of supraphysiological GH levels. This makes sermorelin a "physiological" approach to GH optimization — it amplifies the body's own signaling rather than replacing it.
What Is Sermorelin Used For?
Based on clinical use and published research, sermorelin is used for:
- Growth hormone deficiency — Originally FDA-approved for pediatric GH deficiency; used off-label in adults with age-related GH decline
- Body composition improvement — Research suggests improvements in lean body mass and reductions in body fat (Vittone et al., J Clin Endocrinol Metab, 1997)
- Sleep quality — GH is released primarily during deep sleep; sermorelin may enhance sleep architecture
- Recovery and repair — GH-mediated improvements in tissue recovery
- Anti-aging protocols — Widely used in longevity medicine as an alternative to direct GH administration
- Bone density support — GH plays a role in bone metabolism and turnover
What Are the Risks?
- Injection site reactions. Pain, redness, or swelling at the injection site are the most commonly reported side effects.
- Facial flushing. Transient flushing shortly after injection occurs in some patients.
- Headaches. Mild headaches have been reported, particularly during initial use.
- Dizziness. Some patients experience lightheadedness after injection.
- Reduced effectiveness over time. Some clinicians report diminishing response with prolonged continuous use, which is why cycling protocols are common.
- Contraindicated in active cancer. As with all GH-stimulating compounds, sermorelin should not be used in individuals with active malignancies.
FDA Status
Sermorelin was previously FDA-approved (Geref, 1997) but the branded product was voluntarily discontinued in 2008. It is currently available through licensed compounding pharmacies with a physician prescription. It is classified as Category 1 and has a well-established regulatory pathway for compounding. Of all the peptides commonly used in anti-aging medicine, sermorelin has one of the strongest regulatory foundations due to its prior FDA approval history.
Key Takeaway
Sermorelin is a well-established growth hormone secretagogue with a prior FDA approval history, making it one of the most legally straightforward peptides available through compounding pharmacies.
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.